The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation.

[1]  L Nosek,et al.  Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes , 2012, Diabetes, obesity & metabolism.

[2]  L. Groop,et al.  Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. , 1989, The Journal of clinical investigation.

[3]  R. Bergenstal,et al.  New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2) , 2014, Diabetes Care.

[4]  R. Bergenstal,et al.  New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3) , 2015, Diabetes, obesity and metabolism.

[5]  T. Heise,et al.  New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1 , 2014, Diabetes Care.

[6]  R. Bergenstal,et al.  New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4) , 2015, Diabetes Care.

[7]  A. Mithal,et al.  Clinical use of insulin degludec. , 2015, Diabetes research and clinical practice.

[8]  D. Owens,et al.  Basal insulin analogues in the management of diabetes mellitus: what progress have we made? , 2014, Diabetes/metabolism research and reviews.

[9]  J. DeVries,et al.  New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice , 2015, Diabetes Care.

[10]  P. Home,et al.  New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1) , 2014, Diabetes Care.

[11]  D. Owens,et al.  Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes , 2007, Diabetes Care.

[12]  D. Owens.  Insulin preparations with prolonged effect. , 2011, Diabetes technology & therapeutics.

[13]  F. Porcellati,et al.  Pharmacokinetics and pharmacodynamics of basal insulins. , 2011, Diabetes technology & therapeutics.